» Articles » PMID: 27987076

HOP Expression is Regulated by P53 and RAS and Characteristic of a Cancer Gene Signature

Overview
Publisher Elsevier
Specialty Cell Biology
Date 2016 Dec 18
PMID 27987076
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The Hsp70/Hsp90 organising protein (HOP) is a co-chaperone essential for client protein transfer from Hsp70 to Hsp90 within the Hsp90 chaperone machine. Although HOP is upregulated in various cancers, there is limited information from in vitro studies on how HOP expression is regulated in cancer. The main objective of this study was to identify the HOP promoter and investigate its activity in cancerous cells. Bioinformatic analysis of the -2500 to +16 bp region of the HOP gene identified a large CpG island and a range of putative cis-elements. Many of the cis-elements were potentially bound by transcription factors which are activated by oncogenic pathways. Luciferase reporter assays demonstrated that the upstream region of the HOP gene contains an active promoter in vitro. Truncation of this region suggested that the core HOP promoter region was -855 to +16 bp. HOP promoter activity was highest in Hs578T, HEK293T and SV40- transformed MEF1 cell lines which expressed mutant or inactive p53. In a mutant p53 background, expression of wild-type p53 led to a reduction in promoter activity, while inhibition of wild-type p53 in HeLa cells increased HOP promoter activity. Additionally, in Hs578T and HEK293T cell lines containing inactive p53, expression of HRAS increased HOP promoter activity. However, HRAS activation of the HOP promoter was inhibited by p53 overexpression. These findings suggest for the first time that HOP expression in cancer may be regulated by both RAS activation and p53 inhibition. Taken together, these data suggest that HOP may be part of the cancer gene signature induced by a combination of mutant p53 and mutated RAS that is associated with cellular transformation.

Citing Articles

The Hsp70-Hsp90 go-between Hop/Stip1/Sti1 is a proteostatic switch and may be a drug target in cancer and neurodegeneration.

Bhattacharya K, Picard D Cell Mol Life Sci. 2021; 78(23):7257-7273.

PMID: 34677645 PMC: 8629791. DOI: 10.1007/s00018-021-03962-z.


Dynamically Shaping Chaperones. Allosteric Modulators of HSP90 Family as Regulatory Tools of Cell Metabolism in Neoplastic Progression.

Sanchez-Martin C, Serapian S, Colombo G, Rasola A Front Oncol. 2020; 10:1177.

PMID: 32766157 PMC: 7378685. DOI: 10.3389/fonc.2020.01177.


Structure, Function, and Regulation of the Hsp90 Machinery.

Biebl M, Buchner J Cold Spring Harb Perspect Biol. 2019; 11(9).

PMID: 30745292 PMC: 6719599. DOI: 10.1101/cshperspect.a034017.


Stress-induced phosphoprotein 1 acts as a scaffold protein for glycogen synthase kinase-3 beta-mediated phosphorylation of lysine-specific demethylase 1.

Tsai C, Chao A, Jung S, Lin C, Chao A, Wang T Oncogenesis. 2018; 7(3):31.

PMID: 29593255 PMC: 5874249. DOI: 10.1038/s41389-018-0040-z.

References
1.
Forafonov F, Toogun O, Grad I, Suslova E, Freeman B, Picard D . p23/Sba1p protects against Hsp90 inhibitors independently of its intrinsic chaperone activity. Mol Cell Biol. 2008; 28(10):3446-56. PMC: 2423160. DOI: 10.1128/MCB.02246-07. View

2.
Sepp-Lorenzino L, Rosen N . A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J Biol Chem. 1998; 273(32):20243-51. DOI: 10.1074/jbc.273.32.20243. View

3.
Sandelin A, Carninci P, Lenhard B, Ponjavic J, Hayashizaki Y, Hume D . Mammalian RNA polymerase II core promoters: insights from genome-wide studies. Nat Rev Genet. 2007; 8(6):424-36. DOI: 10.1038/nrg2026. View

4.
Li L, Dahiya R . MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18(11):1427-31. DOI: 10.1093/bioinformatics/18.11.1427. View

5.
Caplan A . What is a co-chaperone?. Cell Stress Chaperones. 2003; 8(2):105-7. PMC: 514860. DOI: 10.1379/1466-1268(2003)008<0105:wiac>2.0.co;2. View